Method for large-scale in-vitro amplification of NK cells and application

By inactivated adenovirus Ad5, the NK cells are activated by efficient amplification in serum-free culture medium, which solves the problems of low efficiency and safety risks of NK cell expansion in the prior art, and achieves large-scale high-purity NK cells Amplified and strong tumor killing activity.

CN119082018APending Publication Date: 2024-12-06GUANGZHOU BLOOD CENT (GUANGZHOU BRANCH OF INST OF BLOOD TRANSFUSION CHINESE ACAD OF MEDICAL SCI GUANGZHOU ORGAN TRANSPLANT MATCHING CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411208615.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently expand high-purity NK cells in vitro in a large scale in the short term, and tumor cells are often added as feeder cells, which poses safety risks.

Method used

NK cells were activated by inactivated adenovirus Ad5, and by activating culture in serum-free culture medium, and amplifying using IL-2 and IL-15 activation cytokines, avoiding the addition of feeder cells and ensuring safety.

Benefits of technology

The NK cells have been expanded by more than 800 times within 15 days, maintaining high purity, and having a strong killing effect on a variety of tumor cells, meeting the needs of clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure F4HMFXUDFDAOQYVD65WPRCQAOD49QCCEJKTAYF4V
    Figure F4HMFXUDFDAOQYVD65WPRCQAOD49QCCEJKTAYF4V
  • Figure GQV730KJFE4S5XDEQDQQ2RLUB2TY2SSLEIREF2L1
    Figure GQV730KJFE4S5XDEQDQQ2RLUB2TY2SSLEIREF2L1
  • Figure PNTJNDI90W6TXAFTZFCTFLSZVINDACGVEJO4N98Y
    Figure PNTJNDI90W6TXAFTZFCTFLSZVINDACGVEJO4N98Y
Patent Text Reader

Abstract

The invention discloses a method for large-scale in-vitro amplification of NK cells and application. The invention relates to a method for large-scale in-vitro amplification of NK (Natural Killer) cells, wherein an inactivated virus for activating the NK cells is adenovirus Ad5. According to the invention, the inactivated virus Ad5 is selected to activate the terminally differentiated NK cells, and the inactivated adenovirus has very strong capability of activating the NK cells, can be massively amplified in a serum-free culture medium, is free of feeder cells and other unknown components, and has good safety. The amplification multiple of the NK cells activated and cultured by the method is more than 800 on the 15th day, and the method has a strong killing effect on various tumor cells, and lays a foundation for large-scale amplification and clinical application of the CAR-NK cells in the future.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a method and application of large-scale in vitro amplification of NK cells. Background Art

[0002] For a long time, the peripheral blood mononuclear cells (PBMCs) in the blood of blood donors have not been fully utilized. Instead, they are removed as waste by centrifugation or filtration, resulting in great waste. If they can be used in the preparation of cell therapy products, they will have broad prospects and abundant resources.

[0003] Natural killer cells (NK) are important components of PBMCs. NK cells derived from healthy blood donors express a wide range of receptors and have mature functions. NK cells are the first line of defense for human immunity and have broad-spectrum anti-tumor and anti-infection effects. NK cell therapy has been widely used in the treatment of tumor killing and viral infections. It has good safety, no graft-versus-host disease (GvHD) and neurotoxicity problems, is a universal ready-to-use product, does not require HLA matching, is suitable for different individuals, and meets the clinical requirements of patients for on-demand use. NK cells are mainly present in the peripheral blood circulation, accounting for about 10% of the total number of lymphocytes, which is a very low proportion, and exist in a terminally differentiated state. Therefore, it is a difficult problem to be solved urgently to expand and culture high-purity NK cells in vitro on a large scale in a short period of time.

[0004] At present, there are many methods for in vitro amplification of NK cells. However, these amplification methods either have low amplification efficiency, generally one hundred to two hundred times, which is difficult to meet the clinical requirements for the number of NK cells. Or they need to add tumor cells as feeder cells, and the amplified NK cells introduce other unknown components, which poses a serious safety hazard. Therefore, it is very necessary to develop a method for in vitro large-scale amplification of NK cells. Summary of the invention

[0005] Based on this, it is necessary to provide methods and applications for large-scale in vitro expansion of NK cells in response to the above-mentioned technical problems.

[0006] The present invention is achieved through the following technical solutions: In a first aspect, a method for large-scale in vitro expansion of NK cells is provided, wherein the inactivated virus for activating NK cells is adenovirus Ad5.

[0007] The method for large-scale in vitro expansion of NK cells specifically comprises the following steps: (1) Add the sorted NK cells to a well plate pre-coated with inactivated Ad5 viral protein for activation culture; do not subculture or change the medium in the first 5 days; (2) On the fifth day of activation culture, the medium was completely replaced and the final concentrations of active cytokines IL-2 and IL-15 were lowered; (3) After the fifth day, NK cells were passaged every other day, counted, and the cell density of the culture was adjusted.

[0008] Furthermore, the final concentration of the inactivated adenovirus Ad5 coating was 5 μg / ml.

[0009] Furthermore, in step (1), the active cytokines in the activation culture medium are IL-2 and IL-15, and the final concentrations used are 1200 IU / ml and 400 IU / ml, respectively.

[0010] Furthermore, in step (2), after the complete medium replacement, the final concentrations of active cytokines IL-2 and IL-15 were adjusted to 400 IU / ml and 200 IU / ml.

[0011] Furthermore, in step (3), the cell density of the culture is 10 6 Cells / ml.

[0012] Furthermore, the NK cells obtained by sorting have a purity of more than 98%.

[0013] In a second aspect, a NK cell is prepared by the method of the first aspect.

[0014] In a third aspect, a pharmaceutical composition comprises: the NK cells of the second aspect above.

[0015] In a fourth aspect, use of the NK cells of the second aspect or the pharmaceutical composition of the third aspect in the preparation of a drug for immunotherapy of solid tumors or hematological tumors.

[0016] Compared with the prior art, the present invention has the following beneficial effects: The present invention selects inactivated adenovirus Ad5 to activate terminally differentiated NK cells. This inactivated adenovirus Ad5 is not infectious, and there is a pre-existing immune response to Ad5 in the population. The inactivated Ad5 has a particularly strong ability to activate NK cells, and is amplified in large quantities in serum-free culture medium without the addition of feeder cells and other unknown components, and has good safety. This method activates cultured NK cells, and the amplification multiple on the 15th day exceeds 800 times, and has a strong killing effect on a variety of tumor cells, laying the foundation for the future large-scale amplification and clinical application of CAR-NK cells.

[0017] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention.

[0018] For better understanding and implementation, the present invention is described in detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the scheme of the present invention, a brief introduction is given below to the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0020] Figure 1 This is a phenotype identification diagram of NK cells obtained by sorting the buffy coat of blood donors in Example 1; Figure 2 For screening a suitable Ad5 virus coating concentration in Example 1; Figure 3 The NK cell expansion experiment results in Example 2; Figure 4 This is a cell phenotype identification diagram on the 15th day of NK cell expansion in Example 2; Figure 5 This is the test result of the in vitro killing activity of the NK cells amplified in Example 3. DETAILED DESCRIPTION

[0021] Hereinafter, examples will be given to illustrate the embodiments of the present disclosure, but the present disclosure is not limited to the examples described below. In the following description, specific numerical values ​​and materials are sometimes exemplified, but other numerical values ​​and materials may also be used as long as the effects of the present disclosure can be obtained. In this specification, a description such as "numerical value A to numerical value B" includes numerical value A and numerical value B, and can be replaced by "numerical value A or more and numerical value B or less". In the following description, when a lower limit and an upper limit are exemplified with respect to numerical values ​​such as specific physical properties and conditions, any one of the exemplified lower limits and any one of the exemplified upper limits can be arbitrarily combined as long as the lower limit does not become above the upper limit. When multiple materials are exemplified, one of them can be selected and used alone, or two or more can be used in combination.

[0022] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0023] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features and technical solutions in the embodiments may be combined with each other.

[0024] It should be noted that similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.

[0025] Example 1 NK cells were isolated from the buffy coat of blood donors and activated and cultured 1.1 Pre-coating 24-well plates with inactivated adenovirus Ad5 Use purified adenovirus Ad5 and inactivate it at 65℃ for 30min. After testing, the inactivated virus is not infectious. Determine the total protein concentration of inactivated adenovirus Ad5. Dilute the inactivated virus total protein with PBS, take 500ul and add it to a 24-well plate, place it in a 4℃ refrigerator, and coat it overnight. The inactivated Ad5 virus can activate terminally differentiated NK cells.

[0026] 1.2 NK cells isolated from the buffy coat of blood donors The buffy coats of 3 healthy blood donors were collected, and the specific steps for NK cell sorting were as follows: (1) Take 5 ml of the remaining buffy coat after the preparation of peripheral blood components from a healthy donor, add 5 ml of PBS and mix well; (2) Slowly add the diluted blood sample into a centrifuge tube containing 10 ml of human lymphocyte separation medium and centrifuge at 400 g for 25 min at room temperature; (3) After centrifugation, the centrifuge tube will have distinct layers, from bottom to top: red blood cell layer, granulocyte layer, Ficoll layer, mononuclear cell layer (buffy coat layer) and plasma layer. The buffy coat layer is aspirated into the centrifuge tube to obtain PBMCs; (4) Count PBMCs and take 1×10 7 The cell solution was sorted using Miltenyi's NK cell sorting reagent; (5) Add 40 μl of pre-chilled PBS to resuspend the cells, then add 10 μl of NK cell antibody solution, mix well and place in a 4°C refrigerator for 15 min.

[0027] (6) Add 30 μl of pre-cooled PBS, then add 20 μl of NK cell microbead solution, mix well and place in a 4°C refrigerator for 5 min.

[0028] (7) The cells were then passed through a sorting column to obtain NK cells, which were counted and set aside. The phenotype of the cultured NK cells was analyzed by flow cytometry after staining with fluorescent antibody 7-AAD (7-aminoactinomycin D), CD3-FITC (FITC-labeled mouse anti-human CD3 antibody) and CD56-APC (APC-labeled mouse anti-human CD56 antibody). The results are shown in Figure 2. Figure 1 As shown, the purity of NK obtained by sorting was over 98%.

[0029] 1.3 Analysis of the appropriate concentration of inactivated Ad5 virus coated plates (1) Dilute the inactivated virus with PBS and coat the plate with different concentrations of 0 μg / ml, 2.5 μg / ml, 5 μg / ml, and 7.5 μg / ml in 24-well plates, and place in a 4°C refrigerator overnight; (2) The NK cells sorted and counted were 2×10 5 The cells / wells were added to a 24-well plate coated with adenovirus Ad5 total protein one day in advance for activation and culture; (3) Take photos to observe the activation of NK cells in the first five days, count them after the fifth day, and compare the activation of NK cells by Ad5 proteins with different coating concentrations to determine the appropriate viral protein concentration for coating the well plate.

[0030] like Figure 2 As shown in A, different concentrations of inactivated Ad5 can activate cultured NK cells to varying degrees, and NK cells show obvious proliferation and aggregation. Figure 2 As shown in B, on the 7th day, the amplification multiples between 5μg / ml and 7.5μg / ml did not increase significantly after counting analysis (P>0.05), but the efficiency of 5μg / ml in activating NK was significantly higher than that of 2.5μg / ml and the control group (P<0.01, the group without inactivated Ad5 virus). In summary, the final concentration of inactivated Ad5 virus coated 24-well plates was determined to be 5μg / ml for subsequent NK cell activation and culture.

[0031] Example 2 Large-scale culture and expansion of NK cells in vitro The sorted and purity-identified NK cells were added to a 24-well plate coated with adenovirus Ad5 total protein one day in advance, and 2×10 5 Cells. Add 2 ml of serum-free NK cell culture medium (IL-2 is 1200 IU / ml, IL-15 final concentration is 400 IU / ml) for activation and culture.

[0032] NK cells were not passaged or replaced during the first 5 days of activation culture. On the fifth day of activation culture, the medium was completely replaced and the final concentrations of active cytokines IL-2 and IL-15 were adjusted to 400 IU / ml and 200 IU / ml. After the fifth day, NK cells were passaged and counted every other day, and the cell density of the culture was adjusted to 10 6 / ml.

[0033] The cells were passaged and counted on days 5, 7, 9, 11, 13, and 15 of NK cell activation culture, and growth curves were drawn, as shown in Figure 3 As shown in the figure, the NK cells activated by inactivated Ad5 expanded more than 800 times on the 15th day, which was significantly higher than the control group (the group without inactivated Ad5 virus). In addition, the NK cells on the 15th day of expansion were stained with fluorescent antibodies 7-AAD, CD3-FITC and CD56-APC, and the phenotype of the cultured NK cells was analyzed by flow cytometry. The results are as follows Figure 4 As shown, the purity of NK is still over 99.5%.

[0034] Example 3 Detection of in vitro cytotoxic activity of large-scale expanded NK cells To further evaluate the in vitro killing activity of the expanded NK cells, the NK cells on the 15th day of expansion were mixed with nasopharyngeal carcinoma cells (HK), human prostate cancer cells (DU145) and human chronic myeloid leukemia cells (K562). These three tumor cell lines were maintained by the laboratory of our unit and cloned to stably express the luciferase reporter gene (Luc). The killing activity of NK cells was evaluated at different effector-target ratios (E:T) of 5:1, 2:1, 1:1 and 0.5:1.

[0035] The specific steps of the killing test include: first, count the target cells (HK, DU145 and K562) respectively, and then plate 10 5 Target cells. After 6 hours, count the NK cells and perform killing tests according to the effector-target ratio (E:T) of 5:1, 2:1, 1:1 and 0.5:1. The final volume of each well is 400ul. Incubate in the incubator for 6-8 hours for killing test. After the incubation, read the luciferase value to evaluate the effect of NK cells killing tumor cells. According to the values ​​of the co-culture wells (Experimental group) and the corresponding wells without effector cells (Control group), calculate the killing rate (Killing effect), the formula is: Killing effect (%) = (control group target cell number - experimental group target cell number) / control group target cell number × 100%, and finally analyze the killing effect.

[0036] The results are as follows Figure 5As shown in the figure, the large-scale expanded NK cells from blood donors have a killing effect on all three tumor cells, and the killing effect is more than 60%, especially the killing effect on tumor cell K562 is the strongest. When the E:T is 2:1, it can achieve 100% killing of target cells, and when the E:T is 1:1, the killing effect is also 40%. In summary, this large-scale in vitro expanded NK cells from blood donors have a very high killing activity against tumor cells.

[0037] Obviously, the embodiments described above are only some embodiments of the present invention, rather than all embodiments. The preferred embodiments of the present invention are given in the accompanying drawings, but they do not limit the patent scope of the present invention. The present invention can be implemented in many different forms. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive. Although the present invention has been described in detail with reference to the aforementioned embodiments, for those skilled in the art, it is still possible to modify the technical solutions recorded in the aforementioned specific embodiments, or to perform equivalent replacements for some of the technical features therein. Any equivalent structure made using the contents of the specification and drawings of the present invention, directly or indirectly used in other related technical fields, is also within the scope of patent protection of the present invention.

Claims

1. A method for large-scale in vitro expansion of NK cells, characterized in that: The inactivated virus that activates NK cells is adenovirus Ad5.

2. The method for large-scale in vitro expansion of NK cells according to claim 1, characterized in that: The steps include: (1) Add the sorted NK cells to a well plate pre-coated with inactivated Ad5 viral protein for activation culture; do not subculture or change the medium in the first 5 days; (2) On the fifth day of activation culture, the medium was completely replaced and the final concentrations of active cytokines IL-2 and IL-15 were lowered; (3) After the fifth day, NK cells were passaged every other day, counted, and the cell density of the culture was adjusted.

3. The method for large-scale in vitro expansion of NK cells according to claim 2, characterized in that: The final coating concentration of inactivated adenovirus Ad5 total protein was 5 μg / ml.

4. The method for large-scale in vitro expansion of NK cells according to claim 2, characterized in that: In step (1), the active cytokines in the activation culture medium are IL-2 and IL-15, and the final concentrations used are 1200 IU / ml and 400 IU / ml, respectively.

5. The method for large-scale in vitro expansion of NK cells according to claim 4, characterized in that: In step (2), after the complete medium replacement, the final concentrations of active cytokines IL-2 and IL-15 were adjusted to 400 IU / ml and 200 IU / ml.

6. The method for large-scale in vitro expansion of NK cells according to claim 2, characterized in that: In step (3), the cell density of the culture is 10 6 cells / ml.

7. The method for large-scale in vitro expansion of NK cells according to claim 2, characterized in that: The NK cells obtained by sorting have a purity of more than 98%.

8. A NK cell, characterized in that: The NK cells are prepared by the method described in any one of claims 1 to 7.

9. A pharmaceutical composition, characterized in that include: The NK cell of claim 8.

10. Use of the NK cell according to claim 8 or the pharmaceutical composition according to claim 9 in the preparation of a drug for immunotherapy of solid tumors or hematological tumors.